Millions of people around the world suffer from upper-limb paralysis.

In other words, they don’t have full use of their arms. Any number of conditions – including stroke, MS, ALS and injury – can cause this to happen.

Myomo has built an orthotic device that can help these patients gain some mobility back.

It’s a remarkable piece of technology. Myomo’s product works by picking up the signals a user’s brain sends to their muscles, then replicating the user’s intended motion with tiny electric motors.

Myomo is currently on its third generation of devices, with the latest models weighing in at just two to four pounds. So far, it’s sold more than 600 units.

Myomo’s products are based on “myoelectric” tech developed at MIT, which is licensed exclusively to the company.

Here’s a picture of one of the company’s orthotic devices.

Myomo’s orthotics are being utilized by patients with many different conditions.

I highly recommend watching this video on YouTube to see how it works. There’s also a nice collection of user testimonials and personal stories on Myomo’s site.

Watching videos of a company’s product in action (when possible) is a crucial part of the due diligence process, and in this company’s case, that’s especially true.

Myomo Taps Regulation A+ Equity Crowdfunding

Last month, Myomo launched an equity crowdfunding round on Banq.co.

The company is raising up to $15 million at a $35 million (pre-money) valuation.

Myomo has previously raised $20 million from Mountain Group Capital and others.

The company was spun out of MIT back in 2006 and has seen steady growth since.

Today, Myomo is working on expanding its network of distributors and getting the device approved by major insurance companies.

Here are some other key points I’ve discovered about Myomo: